Latest Headlines

Latest Headlines

Verona sets sights on PhIIb after COPD drug comes through early trial

Verona Pharma has come through one of the last major barriers between it and the start of a Phase IIb trial of its chronic obstructive pulmonary disease (COPD) drug. The news means that, after years of largely unsuccessful R&D into phosphodiesterase inhibitors, another company is nearly ready to test a product from the class in a late-phase trial.

In latest biopharma-med tech pairing, Teva snaps up respiratory compliance tracker Gecko

In the latest move by a biopharma into med tech, Teva Pharmaceutical will acquire respiratory disease compliance startup Gecko Health Innovations for an undisclosed sum. This gives Teva its own in-house medication compliance tracking capabilities--and takes one of a handful of high-profile startups in this area off the market.

Boehringer finalizes team for crowdsourced COPD R&D initiative

Boehringer Ingelheim has finalized the crowdsourced chronic obstructive pulmonary disease (COPD) R&D team it has spent the past 9 months putting together with BioMed X. The partners have tapped the University of Stuttgart's Renata Jurkowska to lead the initiative, which is an attempt by Boehringer to draw on expertise outside of its walls to better understand the epigenetics of COPD.

FDA expands indication of BI inhaler to include maintenance treatment of asthma

The only inhaler that administers a slow-moving mist to help respiratory patients inhale the medication is now FDA-approved for the long-term maintenance treatment of asthma, in addition to its previous indication to treat COPD.

Boehringer Ingelheim recalls more than 358,000 inhalers

Inhalers can be tricky devices to manufacture and for the second time in two weeks a drugmaker is having to recall inhalers because the devices may not deliver any drugs. Following last week's recall by AstraZeneca of asthma inhalers in Denmark, Boehringer Ingelheim is recalling in the U.S. tens of thousands of inhalers used to treat chronic obstructive pulmonary disease.

Startup partners with AstraZeneca on smart inhalers ahead of Aussie IPO

Melbourne, Australia-based Adherium has pulled off a major pharma partnership just ahead of a proposed listing on the Australian Stock Exchange. It expects to list on Aug. 26, raising up to $35 million and at least $20 million. A new deal that the smart inhaler player just disclosed with AstraZeneca can only enhance its public market prospects.

Study finds Philips ventilator helps reduce hospital readmissions for COPD

Philips touted a study in the Journal of Clinical Sleep Medicine concluding that the company's portable home ventilator greatly reduced hospital readmissions among COPD patients.

Boehringer gets respiratory boost with batch of Spiolto nods in EU

When Boehringer Ingelheim's COPD drug Stiolto Respimat won U.S. approval early last month, the company's head of pharma marketing and sales, Allan Hillgrove, acknowledged that payer arm-twisting happening stateside may make pricing tough. But now, the German drugmaker has nabbed some European approvals that should give the drug a lift.

Pulmatrix hits Wall Street with $10M and a Mylan deal

Respiratory biotech Pulmatrix has completed its nontraditional path to the public markets, closing a merger with upstart Ruthigen to inherit a Nasdaq listing, at the same time banking $10 million and partnering up with generics giant Mylan.

GlaxoSmithKline's new asthma drug gets a split vote from FDA advisers

A group of FDA advisers backed GlaxoSmithKline's latest asthma treatment for use in adults but balked at recommending it for adolescents, setting the stage for a likely approval in the fall.